This round is no longer accepting investments, but hundreds just like it are live now.



Leaders in Home Stroke Recovery

Saebo’s award-winning rehabilitation products offer stroke survivors a second chance to overcome paralysis and regain quality-of-life. Designed specifically for ease-of-use and affordability, Saebo’s products are targeted to unlock the vast untapped market for in-home neurorehabilitation.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$592,631.09 Raised


Stroke is the #1 cause of long-term disability with a market size that is projected to double between 2010 and 2050.

As healthcare costs skyrocket, Saebo’s affordable home-based rehabilitation products improve patient recoveries while lowering the short- and long-term costs of care.

A proven track record with 17 patents awarded, a network spanning six continents and over 40 countries, and $44 million in net revenue to date.

Leaving no patient behind

Saebo is dedicated to bringing accessible, affordable, mobility solutions to all. Committed to “leaving no patient behind” Saebo sets out to create products that could benefit every patient. Saebo’s revolutionary product offering is based on the latest advances in rehabilitation research. From the SaeboFlex to the SaeboMAS, Saebo provides innovative and affordable rehabilitation products.

Saebo has grown into a leading global provider of rehabilitative products created through unrelenting leadership and a strong network of clinicians around the world. As we help over 600,000 clients regain function, we aim to make our newest products more accessible than ever.

The Problem

Stroke rehabilitation equipment is overpriced, ineffective, or too complicated for home use

Every 2.1 seconds, someone in the world suffers a stroke.  For those who are lucky enough to survive, overcoming paralysis can take months or even years of intense therapy.  

Too often, patients are treated in facilities that do not offer the latest advances in stroke rehabilitation technology. Then, they are often sent home with no effective home program and without the tools and resources they need to recover. Most at home stroke rehabilitation technology is overpriced, ineffective, or too complicated for home use.

All along the way, doctors routinely misinform stroke patients about the potential for additional recovery. Many patients are told that they have reached a recovery “plateau” and additional progress is no longer possible.

Without help, patients experience worsening paralysis, decreased range-of-motion, increased pain and depression, and a deteriorating quality-of-life. 

Making matters worse, even in developed countries like the U.S., insurance rarely covers the cost of long-term therapy or innovative rehabilitation products. 

The latest research demonstrates that it doesn’t have to be this way. Today, we now know that recovery can continue for many years, even decades, but only if patients get the help they need. 

The Solution

Providing effective and affordable rehabilitation products delivered directly to the patient’s home

Saebo creates effective, safe, and affordable products allowing every patient to maximize their neurological recovery, from the clinic to the home.

  • Each of our exclusive, easy-to-use products is designed and vetted by experienced, practicing clinicians. 

  • Our products are backed by years of clinical research and designed for simple use at home. 

  • Our FDA approved and non-invasive devices are affordable, even to those without insurance coverage. 

Our portfolio of products help stroke patients overcome a variety of impairments and maximize their recovery.

We have a product or service for every patient looking to improve their recovery at home.

And, because our products are guaranteed to be effective, affordable, and easy-to-use, patients can order any product on our website and enjoy a 30-Day Money-Back Guarantee.  We also provide a free evaluation, expert advice, and follow-up clinical support with each order.


Our Traction

Saebo is a trusted brand with global reach

Our lifetime net revenue is at over $44 million and we’ve seen tremendous growth to-date across our B2B and B2C sectors:

  • A distributor network spanning 6 continents and over 40 countries

  • 17 Patents: our innovative product designs have been awarded 17 different patents by the US Patent Office

  • FDA clearance: our products has already satisfied FDA pre-marketing requirements or are regulated as class I devices, which are exempt from premarket requirements

  • Global adoption: Our products have been used by an estimated 800,000 patients in more than 4,000 hospitals around the world. 

Additionally, our products are recommended by the 10 top rehabilitation hospitals in the US (as ranked by US News and World Report). Our products and treatment approaches have now been featured in 20 different medical textbooks and publications, authored by the top neurologists and professors around the world. Saebo products and programs are featured in numerous university curriculums around the world.

Our very first product, the SaeboFlex, was recently put on permanent display at the London Science Museum alongside other breakthrough medical technologies such as penicillin and the first MRI.

The Business Model

A multi-channel distribution system, secured with high lifetime value

With over $44 million in net revenue to date, Saebo has a well-established multi-channel business model.

We sell products directly to the end-user through our D2C e-commerce platform. This platform leverages clinical expertise, producing educational content that generates over 250,000 website visits per month. This has paved the way for our significant digital footprint.

Another primary revenue stream is our B2B channel. We sell products directly to hospitals and treatment centers for use in the care of their patients. 

We also sell our products through various domestic and international healthcare providers and medical product distributors. This hybrid approach leverages a wide network of international distributors, who can then leverage their insurance networks and/or provider networks to navigate local compliance and logistics issues.

We have seen steady growth to-date across all of these channels:

  • 90% compound annual growth rate (CAGR) for products sold to US patients through our ecommerce platform since 2017.

  • 27% compound annual growth rate (CAGR) for direct-to-patient unit product sales between 2013 and 2018.

  • 10% compound annual growth rate (CAGR) for equipment sold to hospitals between 2013 and 2018.

And our multi-channel approach is now delivering scalable, capital-efficient growth opportunities based on falling customer acquisition costs and increasing customer lifetime values. Our current cost-per-acquisition is around $45 and our estimated lifetime value is about $300 per customer and rising.

The Market

Stroke is the #1 cause of long-term disability worldwide

Saebo is a well-established leader in the neurorehabilitation market for a significant population of stroke survivors:

  • Globally, there are over 15 million stroke survivors (source).

  • The U.S. alone is home to over 6.4 million stroke survivors with another 800,000 new survivors every year (source).

  • Between 2010 and 2050 the number of strokes in the U.S. is projected to double (source).

  • By 2030, almost 4% of US adults will have had a stroke (source).

  • Roughly 70% of stroke survivors are 65 or older; one of the fastest-growing demographics in the developed world (source).

  • Stroke is the number one cause of long-term adult disability worldwide (source).

  • The total direct annual stroke-related medical costs are projected to increase from $71 billion in 2012 to $183 billion by 2030 (source).

Consistent, long-term growth in the worldwide market for stroke rehabilitation products will be driven by a number of factors including:

  • Increasing stroke incidence levels due to changing demographics and lifestyles (as people live longer, they are more likely to have a stroke at some point in their lives).

  • Increasing stroke survival rates due to advances in acute medical care (growing number of survivors means more require post-stroke rehabilitation).

  • Increasing demand for new technologies due to advances in neuroscience (new evidence on cortical plasticity is demonstrating that old approaches to treatment are no longer adequate)

And finally, with COVID-19, we have seen an increased incidence of stroke. Particularly with pandemic restrictions, there is an increased urgency and demand for effective in-home therapy.

What we do

Improving stroke rehab: Reimagining what’s possible.

From hospital to home, our products and services support patients each step of the way.  Our patient-targeted solutions are designed to meet three simple criteria: 

  1. Proven Efficacy: every product we sell is based on treatment principles backed by science and years of clinical research

  2. Affordability: we focus on making every product we sell as affordable as possible; in fact, we even have several products and services that we offer for free!

  3. Ease-of-use: our products are vetted by clinicians with years of hands-on experience helping patients in real-world settings 

We also devote many of our resources to educating patients and clinicians around the world about the latest advancements in treatment and how our products incorporate those treatment paradigms.

Saebo Academy is approved by the American Occupational Therapy Association to provide accredited continuing education courses to clinicians. To date, more than 20,000 therapists have participated in our educational programs worldwide.

Our technology and ever-expanding product base continue to grow, with 17 existing patents, demonstrating our unique and innovative technologies.

Saebo has been a worldwide leader in stroke rehabilitation since 2004 and continues to lead the way for patient recovery-focused solutions.

The Vision

A Helping Hand For Every Patient

At Saebo, we believe every patient deserves a helping hand. That means empowering patients with the education, tools, and financial assistance they need to take control of their own recovery.

Today, Saebo is considered by many to be the foremost leader in stroke rehabilitation. Tomorrow, we look forward to bringing our expertise to an ever-expanding range of neurological conditions and impairments.

The stroke survivor population is only the beginning. We also help treat veterans with traumatic brain injuries at VA centers across the country. Millions suffering from Multiple Sclerosis, neuropathy, and other neurological disorders could benefit from our technology.


Decades of Diverse Expertise

With a combined 112 years of clinical experience and 49 years of management experience, the Saebo team is made up of exceptional leaders in business and medicine, poised to change the lives of patients around the world. 

Why Invest

We’ve helped about 1 million stroke patients worldwide. 79 million to go.

To continue to provide life-changing solutions for those suffering from impaired mobility and function, Saebo aims to expand global partnerships and provide directly accessible devices for every patient who needs them.

We hope to follow our momentum with funding from StartEngine for new product development, lower-cost product sourcing, a sophisticated DTP digital marketing platform, and additional domestic and international distribution channels and partners. We hope you will join the charge to provide innovative, affordable, and positively impactful solutions so that no patient is ever left behind.


Quick Insert


2459 Wilkinson Blvd. Ste 120-B
Charlotte, NC 28208

Saebo’s award-winning rehabilitation products offer stroke survivors a second chance to overcome paralysis and regain quality-of-life. Designed specifically for ease-of-use and affordability, Saebo’s products are targeted to unlock the vast untapped market for in-home neurorehabilitation.


Henry Hoffman
Henry Hoffman
Co-Founder and President
Most known for co-creating the revolutionary SaeboFlex exoskeleton for stroke recovery which is currently on permanent display at the London Museum of Science, Henry holds 17 patents with products that have helped tens of thousands of patients regain function.

As an occupational therapist, Henry has worked in a variety of clinical settings including home health, acute, sub-acute, and outpatient rehab. Prior to leaving Burke Rehabilitation Hospital in New York in 2002, he worked as a clinical specialist in stroke and orthopedic medicine and manual therapy of the upper quadrant. After leaving Burke, Henry co-founded Saebo, with the goal of creating innovative and life-changing solutions for the physically impaired population. He currently holds 17 patents with products that have helped tens of thousands of clients regain function. Saebo's name is an acronym for Henry’s grandmother "Sarah Eileen Booth". Her entire life was dedicated to providing a hand to others in need. Saebo’s mission is to match her spirit, dedication, and desire to help others.

Todd D. Wiebusch

Todd D. Wiebusch

Executive Chairman

Todd is an experienced health care investor and operator with 30 years of experience in the DME, Home Health, Hospice, SNFs/ALFs and Rehabilitation industries. He spends about 50% of his time on Saebo. He is also a partner in, an early-stage VC fund based in Helsinki, Finland investing in digital health and wellness companies that aspire to enter the US Market. Since 2016 he has served as Honorary Consul of Finland for North and South Carolina.
Peter Durand

Peter Durand


Pete had a successful early corporate career at companies like Kimberly Clark, Eaton and General Electric, and after working in several startups, he was inspired to start RivalHealth in 2009, a company delivering fully customized and individual fitness solutions. In 2017, after changing thousands of people’s lives, he merged the company with gBehavior to form GoPivot Solutions, the leading well-being platform in the US.  

Pete went on to form Cruxible Partners, a boutique consulting and talent acquisition firm in 2018. After consulting with Saebo, Inc. he joined the company as CEO in early 2022. Pete was excited to marry his passion for health and Saebo’s mission to leave no stroke patient behind.

He is patent holder, a podcast host, an accomplished triathlete, exercise junkie, nutrition nut and NASM Certified Personal Trainer (CPT). Pete holds a BS in Industrial Engineering and MBA and is a former Ernst & Young Entrepreneur of the Year for the Carolinas.

Alan Zdyb

Alan Zdyb

VP Finance

Finance executive with 35 years of experience in auditing and in financial operations of growing health care companies. Alan's areas of expertise include financial reporting, cash flow management, risk management, and human resources. Alan began his career in public accounting with Peat Marwick & Mitchell (now KPMG) where he advanced his career to the manager level while successfully passing the CPA exam. He worked for a growing Durable Medical Equipment and Home IV therapy company as Receivables Management Director. He then was Controller of a multi-location nursing home company with responsibility for most areas of the financial operations and reporting. For the last 19 years, Alan has worked for CHMG Solutions or its predecessors as Controller and now VP Finance. Alan spends approximately 10 hours per week working on Saebo-related issues, projects, etc., and is responsible for all financial functions and reporting for Saebo and many other related companies, primarily home health care and assisted living companies. 
Christopher Klett

Christopher Klett

Chief Operating Officer

With executive roles in finance, operations, and marketing, Chris has over 30 years of experience in the healthcare, direct-to-consumer, and retail markets.

With a passion for early-stage companies, Chris joined Saebo in its first year of operations and has enjoyed overseeing the back-office, warehouse and distribution operations, while also directing the reimbursement, compliance, and marketing strategies as Saebo's full-time COO. Prior to joining Saebo, Chris built his experience in the healthcare sector as Director of Mergers and Acquisitions for CHMG Capital. Chris received his BA in Economics from Davidson College.

Sean Jones

Sean Jones

Director of Supply Chain

His job requirements involve the management of raw and finished Goods, Assembly, Imports and Exports, Purchasing, and Quality Control.

Sean has worked in the manufacturing/production field for over 20 years and has been with Saebo for the last 10 years. Before joining Saebo he ran three manufacturing plants at one time for a Multinational craft company. While attending college for a business degree in management, he started working in the plants learning the different tasks in various departments from the bottom up. This has given him a solid foundation consisting of academic knowledge as well as hands-on experience.

Dr. Scott Thompson

Dr. Scott Thompson

Director of Clinical Services

With executive roles in clinical and educational development, Scott has experience in almost every type of medical setting and managerial role possible.

A seeker of knowledge, Scott holds Masters and Doctorate degrees in Occupational therapy, with advanced certifications in neurological treatment. While he is a full time (40 hours/week) employee of Saebo, he also participates in professional duties by holding advisory board positions for two occupational therapy schools and sits as an executive board member of his state’s occupational therapy association and foundation.

Dr. Steve Wolf

Dr. Steve Wolf

Advisory Board Member

Dr. Wolf is a physical therapist and neuroscientist. His primary interests have been in researching ways to improve movement capabilities in aging and neurological populations. Until recently he also spent considerable time evaluating and treating patients diagnosed with stroke. He is past vice president of the Physical Therapy Association of Georgia and recipient of its Merit Award. While he has received numerous awards, those most relevant include: The Golden Pen Award, Lucy Blair Service Award, and The Helen J. Hislop Award for Outstanding Contributions to Literature. He has been a Catherine Worthingham Fellow of the APTA since 1987 and was the 2002 Mary McMillan Lecturer. 

Dr. Wolf’s professional contributions include establishing the inclusion criteria for forced use of the upper extremity following stroke and contributing to the formulation of what later became known as constraint-induced movement therapy, establishing Tai Chi as a falls’ prevention exercise for older adults, and helping to establish what is today known as the FiRST (Frontiers in Rehabilitation Science and Technology) Council of the APTA. Considered by some to be a bit of a visionary, he has received honors from multiple professional organizations, has authored or co-authored over 270 refereed articles; edited 9 books; procured over $70M in grant funding; and has provided over 800 national and international lectures.

Dr. Wolf spends up to approximately 5 hours per month, as needed, consulting with Saebo on education topics, product development and industry trends.

Glyn Blakey

Glyn Blakey

Managing Director, SaeboUK

A chartered physiotherapist specializing in stroke rehabilitation leading the Saebo UK limited company. 

Glyn has worked with the National Health Service and private practice as a clinical specialist in stroke rehabilitation. He now enjoys his active managing director role as an educator within the stroke rehabilitation industry. He has played a pivotal role is setting up the European Saebo distributorships.

Amy Bean

Amy Bean

Clinical Specialist

Amy is a Neurological Physiotherapist with over 18 years of clinical experience. Amy provides clinical support, training, and sales support for Saebo in the UK.  

Amy has grown her clinical experience in a variety of locations within the National Health Service in the UK, and also in private health care in Australia. Her switch to working with Saebo for the last 11 years comes from seeing the significant difference in rehabilitation outcomes using the Saebo range in her previous clinical role in Stroke Rehabilitation. 


Jun. 1, 2022 at 6:59 AM UTC
$10k - $1.07M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Votings Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the President of the Company (the “President”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the President determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the President for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*


Friends and Family Early Birds

Invest within the first 48 hours and receive an additional 20% bonus shares.

Super Early Bird Bonus

Invest within the first week and receive an additional 15% bonus shares.

Early Bird Bonus

Invest within the first two weeks and receive an additional 10% bonus shares.



Supporter Level

Supporters will receive a $25 gift card for the products or swag of your choice at You’ll also receive a personalized coupon code to save 20% on any product of your choice.*


Bronze Investor Level

Bronze Investors will receive a $50 gift card for the products or swag of your choice at You’ll also receive a coupon code to save 20% on your entire next order.*


Silver Investor Level

Silver Investors will receive a $100 gift card for the products or swag of your choice at You’ll also receive a personalized coupon code to save 20% on all of your orders for an entire year.*


Gold Investor Level

Gold Investors will receive 10% Bonus Shares plus all of the Silver Level perks. In addition, Saebo will donate, in your name, $500 worth of products to patients in need.


Platinum Investor Level

Platinum Investors will receive 15% Bonus Shares plus all of the Silver Level perks. In addition, Saebo will donate, in your name, $1,000 worth of products to patients in need.

*Excludes hospital-based treatment equipment (e.g., items priced over $5,000).

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Saebo, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $0.50 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $50. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

We will not incur any irregular use of proceeds.


Article Image
Sioux City Journal: Devices help stroke patients regain hand, arm functionality

SaeboFlex supports Bradley Collins' wrist, allowing him to extend his left thumb and fingers in order to grasp and release objects.

Article Image
BusinessWire: Hocoma and Saebo Partner to Deliver Compact, Affordable Rehabilitation Solution for Upper Extremities

Together, the SaeboMas Mini and the ArmeoSenso deliver an easy-to-use, compact solution at an affordable price.

Article Image
The Telegraph: Long Blondes guitarist uses 'bionic hand' after stroke

The 27-year-old guitarist in popular indie band The Long Blondes hopes to play again despite suffering a stroke, thanks to cutting-edge medical technology.

Article Image
Live 5 News MUSC Health Connection (CBS): MUSC Patient Fitted with SaeboFlex

Article Image
Petosky News Review: Cutting-edge equipment changes life of local stroke victim

Michael Seiler using the SaeboFlex during a rehabilitation session. After suffering a stroke in 2011, Seiler has put in years of hard work and continues to make progress with the Saebo equipment.



Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Saebo.
Owners bonus

Owner’s Bonus

Owner’s Bonus Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).




Denise Colella

3 years ago

I am also a major stroke survivor/investor. These products work and are much needed BtoC. They changed/saved my life.




Bradley Short

3 years ago

As a Physiatrist and in practice for over 28 years, I am quite familiar with those inflicted with strokes... I am also familiar with SAEBO products... They are revolutionary and truly excellent.



Diana Priego

a year ago

I am also waiting for my rewards too? My son uses your products.



William Larsen

a year ago

I'm am a stroke survivor & use many Saebo products. I love your products which have helped in my recovery. This is one of a number of reasons why I invested in Saebo. When will I receive my investment incentives? I am looking at purchasing more Saebo products very soon. Looking forward to your reply. Thanks! Bill Larsen



Troy Gibson

a year ago

Troy G. Here. question, my investment/shares in Saebo. If something were to happen to me will my shares go to a beneficiary. How does this work ? Thanks



Manuel Marques

2 years ago

Good afternoon, I invested during the December campaign and am now looking to place an order for my mother. Where would I locate the coupon code/discount code for my investor level perk? Thank you in advance.



Manuel Morales Wyden

2 years ago

Hello! Is it still not possible to make an investment outside of the U.S.? - would be very interested in doing so - keep up the good work and thanks for the reply!



Steve Mills

2 years ago

What has been the response from the insurance industry? I saw a statement..."affordable even without insurance." How much of what you offer is covered under an average insurance plan? Would/could these aids be covered under Medicare? It seems to me, if this can save the insurance companies money, they'll be a major influence in scaling the company.



Adam Forster

2 years ago

Does the new Saebostim Spa help w foot pain from neuropathy? Product looks nice. Great work. Thanks.



Paul Tuscano

2 years ago

The product sound great and it seems like you are doing well. I am curious what you need the funding for? I saw a response below saying that you were going to develop newer products. I would think you would want to optimize the margins and volumes sold of the existing products before pursuing other products. If profitability is a concern despite having good products which are defensible then you have an operating model problem and need to focus. You might want to consider cutting back or pausing some of your other products which might be less successful and carry a higher operating cost.




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!


With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


Get To Know Us

Our Team



Important Message

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA / SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from (the any security. It also does not constitute an offer to provide investment advice or service. any security. It also does not constitute an offer to provide investment advice or service. any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC.